EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) Is Effective in Reducing Symptoms of Huntington’s Disease in Females of the R6/1 Mouse Model

Lidia Gaffke, Estera Rintz, Dorota Myślińska, Magdalena Podlacha, Karolina Pierzynowska, Grzegorz Węgrzyn

Frontiers in Bioscience-Landmark · 2026

DOI: 10.31083/fbl51780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von Lidia Gaffke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Faculty of Biology, University of Gdansk, 80-308 Gdansk, Poland. Hauptthemen laut MEDLINE: Genistein, Huntington Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, Poland, START scholarship from Foundation for Polish Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background:Huntington’s disease (HD) is an inherited (autosomal dominant) disorder caused by the occurrence of a pathogenic variant of the HTT gene. The genetic defect consists of an expansion of CAG repeats in exon 1, resulting in the production of a toxic misfolded huntingtin protein that forms aggregates. Currently, there is no registered therapy for this severe, neurodegenerative disease. Recent studies have demonstrated that treatment with genistein (4′,5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one), which acts by stimulating autophagy through a FOXO3-dependent process, can ameliorate behavioral abnormalities and improve biochemical parameters in the R6/1 mouse model of HD. However, although HD occurs in humans with similar frequency in men and women, the effects of high dose (150 mg/kg/day) of genistein on HD mice were tested previously only in males, because of concerns regarding potential ambiguity in interpretation of the results caused by structural similarities between genistein and estrogens. Nevertheless, as potential anti-HD therapies should be evaluated in both sexes, in this work the effects of genistein administration on behavior, levels of selected hormones, and biochemical parameters were evaluated in R6/1 female mice.Methods:Several behavioral tests, including the Rota-rod test, elevated-plus maze, open field test, and Morris water maze, were performed using R6/1 (HD) and control female mice treated with or without genistein at 150 mg/kg/day. We determined the levels of selected hormones and biochemical parameters in these animal groups. Genistein treatment was initiated at 16 weeks of age, shortly after the onset of symptoms at 14 weeks of age, and tests were conducted at 16, 22, and 30 weeks of age.Results:Genistein was effective in improving behavioral outcomes (p < 0.05 for all tests vs untreated animals) and improving hormonal and biochemical parameters (p < 0.05 for all tests) in female R6/1 (HD), similarly to results reported previously for males of the same line.Conclusion:Genistein effectively reduced symptoms of HD in both male and female R6/1 mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GenisteinHuntington DiseaseAnimalsFemaleDisease Models, AnimalMiceMaleMice, TransgenicBehavior, Animal

Stichwörter der Autor:innen

Huntington’s diseasebehavioral testsgenisteinhormoneslaboratory micereactive oxygen species

Substanzen

Genistein

Autor:innen und Institutionen

  • Department of Molecular Biology, Faculty of Biology, University of Gdansk, 80-308 Gdansk, Poland.
  • Department of Animal and Human Physiology, Faculty of Biology, University of Gdansk, 80-308 Gdansk, Poland.

Förderung

  • National Science Center, Poland
  • START scholarship from Foundation for Polish Science

Zitieren

APA

Gaffke, L., Rintz, E., Myślińska, D., Podlacha, M., Pierzynowska, K., & Węgrzyn, G. (2026). Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) Is Effective in Reducing Symptoms of Huntington’s Disease in Females of the R6/1 Mouse Model. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl51780

Vancouver

Gaffke L, Rintz E, Myślińska D, Podlacha M, Pierzynowska K, Węgrzyn G. Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) Is Effective in Reducing Symptoms of Huntington’s Disease in Females of the R6/1 Mouse Model. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl51780

BibTeX
@article{Gaffke2026,
  author = {Gaffke, Lidia and Rintz, Estera and Myślińska, Dorota and Podlacha, Magdalena and Pierzynowska, Karolina and Węgrzyn, Grzegorz},
  title = {Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) Is Effective in Reducing Symptoms of Huntington’s Disease in Females of the R6/1 Mouse Model},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  doi = {10.31083/fbl51780}
}
Kostenlos starten →